Clinical Report: Utilization of Mesenchymal Stem Cells in Pediatric ARDS

Overview

This review discusses mesenchymal stem cells (MSCs) and their exosomes (MSC-Exos) in the context of pediatric Acute Respiratory Distress Syndrome (ARDS) and the evolving role of nursing in integrating these therapies into clinical practice.

Background

Pediatric ARDS is a critical condition with high mortality rates and limited treatment options. Current management strategies primarily focus on supportive care, which does not address the underlying pathophysiology. The exploration of MSCs and MSC-Exos represents a shift towards targeted therapies.

Data Highlights

No numerical data available in the source material.

Key Findings

• MSCs possess unique immunomodulatory and regenerative properties.
• MSC-Exos are nanoscale extracellular vesicles that mediate many therapeutic effects of MSCs.
• Current challenges include optimizing cell sourcing, exosome isolation, and navigating regulatory hurdles.
• Nursing roles are evolving to include advanced process management for biotherapeutic modalities.

Clinical Implications

The integration of MSC and MSC-Exos therapies into pediatric ARDS management necessitates a comprehensive understanding of cellular biology among nursing staff.

Conclusion

The application of MSC and MSC-Exos therapies in pediatric ARDS highlights the critical role of nursing in this evolving landscape.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Beyond Immunomodulation: Mechanisms and Synergistic Strategies of Mesenchymal Stem Cells in Promoting Alveolar Epithelial and Endothelial Repair in ARDS
2. Frontiers in Pediatrics, 2026 -- Mesenchymal stem cell therapy as adjunctive treatment in pediatric patients with severe acquired brain injury: a single-center retrospective case series
3. Frontiers in Medicine, 2026 -- Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned
4. Frontiers in Immunology, 2026 -- The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial
5. PubMed, 2025 -- Treatment with Allogeneic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multicenter Phase 2b Clinical Trial (STAT)
6. PALICC-2 Consensus Guidelines for Pediatric ARDS
7. Treatment with Allogeneic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multicenter Phase 2b Clinical Trial (STAT) - PubMed
8. Dynamic Stem Cell Therapy - 712579 - 02/11/2026 | FDA